A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT04166773 · Completed

Last updated 2026-05-28

This clinical trial is testing the drug tirzepatide in adults with nonalcoholic steatohepatitis (NASH) to see if it can improve liver health without worsening fibrosis.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 190 people

Who can join Ages 18–80 · all sexes

Timeline Started 2019-11 · est. completion 2024-01

Where 112 sites · Belgium, France, Israel, Italy, Japan, Mexico, Poland, Spain, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT04166773 ↗

Description as written by the study sponsor.

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology
Sponsor	Eli Lilly and Company
Conditions studied	Nonalcoholic Steatohepatitis
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04166773 ↗